Experimental and Clinical Evaluation in Man of Hexamethonium (C6), A New Ganglionic Blocking Agent

In this follow-up to an earlier article by several British researchers, Finnerty and Freis confirmed that Hexamethonium acted longer and produced a greater degree of sympathetic blockade than tetraethylammonium, a ganglion-blocking agent that was found to be a poor treatment for chronic hypertension.

Presented in part before the national meeting of the American Federation of Clinical Research, Atlantic City, New Jersey, May, 1950.